United Capital Financial Advisors’s Royalty Pharma RPRX Stock Holding History

United Capital Financial Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Sell	4,313 -3,367	-44%	-$175K	﹤0.01%	1467
2026 Q1	$368K	Buy	+7,680	New	+$336K	﹤0.01%	1227
2023 Q1	–	Sell	-74,376	Closed	-$2.94M	–	1056
2022 Q4	$2.94M	Buy	74,376 +38,103	+105%	+$1.59M	0.02%	410
2022 Q3	$1.46M	Sell	36,273 -3,892	-10%	-$166K	0.01%	530
2022 Q2	$1.69M	Buy	+40,165	New	+$1.65M	0.01%	524

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

United Capital Financial Advisors's RPRX Position: Q2 2026 in Review

United Capital Financial Advisors reduced its Royalty Pharma (RPRX) stake by 44% in Q2 2026, selling an estimated $175K and leaving 4,313 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

United Capital Financial Advisors first reported a position in RPRX in Q2 2022 and has held it in 5 quarters since. The position peaked at $2.94M in Q4 2022. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

United Capital Financial Advisors held 4,313 shares of Royalty Pharma worth $242K as of Q2 2026.
United Capital Financial Advisors sold 3,367 Royalty Pharma shares in Q2 2026, an estimated $175K.
Royalty Pharma made up ﹤0.01% of United Capital Financial Advisors's portfolio in Q2 2026, its #1467 holding.
United Capital Financial Advisors first reported a position in Royalty Pharma in Q2 2022 and has held it in 5 quarters since.
United Capital Financial Advisors's Royalty Pharma position peaked at $2.94M in Q4 2022.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.